KRAS and cancer: Ross et al. described the use of an ethyl-containing ASO (AZD4785) to downregulate KRAS mRNA, which is mutated in approximately 20% of human cancers, and demonstrated its efficacy in preclinical KRAS mutant lung cancer models (Ross et al., 2017).